Atul Varadhachary
Chief Executive Officer Radiomer Therapeutics
Atul Varadhachary, MD, PhD, is a physician-scientist with more than three decades of experience in therapeutic product development. He is also deeply committed to mentorship, talent development, and community and philanthropic initiatives. Dr. Varadhachary completed his medical training at the University of Mumbai and earned his PhD from the Johns Hopkins School of Medicine.
He is currently the CEO of Radiomer Therapeutics, where he leads the development of targeted radiopharmaceutical and radioligand therapies based on the company’s novel Raptamer platform. Under his leadership, Radiomer—an innovative spin-out from Fannin—is advancing its pipeline toward first-in-human studies, with its lead program expected to enter the clinic in the first half of 2025.
Seminars
- Expanding radiopharmaceutical reach by drugging first-in-class targets COF-01 and ALT-01
- Optimizing tumor delivery through intelligent ligand design and tunable pharmacokinetics
- Accelerating clinical translation with a data-driven selection and prioritization framework
New Company for 2026
